Company registration number 07663803 (England and Wales)
CONSTRUCTIVE MEDICAL LIMITED
ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2024
PAGES FOR FILING WITH REGISTRAR
CONSTRUCTIVE MEDICAL LIMITED
COMPANY INFORMATION
Director
Mr N A Boyes
Company number
07663803
Registered office
C/O Xeinadin First Floor Secure House
Lulworth Close
Chandler's Ford
Southampton
Hampshire
England
SO53 3TL
Accountants
Xeinadin South East Limited
12 Conqueror Court
Sittingbourne
Kent
United Kingdom
ME10 5BH
CONSTRUCTIVE MEDICAL LIMITED
CONTENTS
Page
Director's report
1
Accountants' report
2
Balance sheet
3
Notes to the financial statements
4 - 6
CONSTRUCTIVE MEDICAL LIMITED
DIRECTOR'S REPORT
FOR THE YEAR ENDED 30 JUNE 2024
- 1 -

The director presents his annual report and financial statements for the year ended 30 June 2024.

Principal activities

The principal activity of the company in the year under review was that of distribution of medical supplies

Director

The director who held office during the year and up to the date of signature of the financial statements was as follows:

Mr N A Boyes
Small companies exemption

This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies exemption.

On behalf of the board
Mr N A Boyes
Director
25 February 2025
CONSTRUCTIVE MEDICAL LIMITED
REPORT TO THE DIRECTOR ON THE PREPARATION OF THE UNAUDITED STATUTORY ACCOUNTS OF CONSTRUCTIVE MEDICAL LIMITED
- 2 -

These financial statements have been prepared in accordance with our terms of engagement and in order to assist you to fulfil your duties under the Companies Acts that relate to preparing the financial statements of the company for the year ended 30 June 2024.

We have prepared these financial statements based on the accounting records, information and explanations provided by you. We do not express any opinion on the financial statements.

On the balance sheet, you have acknowledged your duties under the prevailing Companies Acts to ensure that the company keeps adequate accounting records and prepares financial statements that give a true and fair view.

You have determined that the company is exempt from the statutory requirement for an audit for this accounting year. Therefore, the financial statements are unaudited.

 

The financial statements are provided exclusively to the director for the limited purpose mentioned above, and may not be used or relied upon for any other purpose or by any other person, and we shall not be liable for any other usage or reliance.

Xeinadin South East Limited
12 Conqueror Court
Sittingbourne
Kent
ME10 5BH
United Kingdom
25 February 2025
CONSTRUCTIVE MEDICAL LIMITED
BALANCE SHEET
AS AT
30 JUNE 2024
30 June 2024
- 3 -
2024
2023
Notes
£
£
£
£
Fixed assets
Tangible assets
3
1,418
1,842
Current assets
Debtors
4
1,784
1,789
Cash at bank and in hand
1,562
853
3,346
2,642
Creditors: amounts falling due within one year
5
(12,880)
(24,742)
Net current liabilities
(9,534)
(22,100)
Net liabilities
(8,116)
(20,258)
Capital and reserves
Called up share capital
100
100
Profit and loss reserves
(8,216)
(20,358)
Total equity
(8,116)
(20,258)

For the financial year ended 30 June 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The member has not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The director of the company has elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved and signed by the director and authorised for issue on 25 February 2025
Mr N A Boyes
Director
Company registration number 07663803 (England and Wales)
CONSTRUCTIVE MEDICAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2024
- 4 -
1
Accounting policies
Company information

Constructive Medical Limited is a private company limited by shares incorporated in England and Wales. The registered office is C/O Xeinadin First Floor Secure House, Lulworth Close, Chandler's Ford, Southampton, Hampshire, England, SO53 3TL.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, [modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value]. The principal accounting policies adopted are set out below.

1.2
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

 

When cash inflows are deferred and represent a financing arrangement, the fair value of the consideration is the present value of the future receipts. The difference between the fair value of the consideration and the nominal amount received is recognised as interest income.

1.3
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Fixtures and fittings
15% on reducing balance
Motor vehicles
25% opn reducing balance

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.4
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

CONSTRUCTIVE MEDICAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2024
1
Accounting policies
(Continued)
- 5 -
Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

 

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2024
2023
Number
Number
Total
1
1
3
Tangible fixed assets
Fixtures and fittings
Motor vehicles
Total
£
£
£
Cost
At 1 July 2023 and 30 June 2024
1,798
3,495
5,293
Depreciation and impairment
At 1 July 2023
1,430
2,021
3,451
Depreciation charged in the year
55
369
424
At 30 June 2024
1,485
2,390
3,875
Carrying amount
At 30 June 2024
313
1,105
1,418
At 30 June 2023
368
1,474
1,842
4
Debtors
2024
2023
Amounts falling due within one year:
£
£
Trade debtors
1,784
1,789
CONSTRUCTIVE MEDICAL LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2024
- 6 -
5
Creditors: amounts falling due within one year
2024
2023
£
£
Trade creditors
384
540
Taxation and social security
2
1
Other creditors
12,494
24,201
12,880
24,742
6
RELATED PARTY DISCLOSURES

The company was under the control of Mr N A Boyes throughout the current and previous periods. Mr N A Boyes is the sole director and a shareholder.

2024-06-302023-07-01falsefalsefalse25 February 2025CCH SoftwareCCH Accounts Production 2024.301No description of principal activityMr N A Boyes076638032023-07-012024-06-3007663803bus:Director12023-07-012024-06-3007663803bus:RegisteredOffice2023-07-012024-06-30076638032024-06-30076638032023-06-3007663803core:FurnitureFittings2024-06-3007663803core:MotorVehicles2024-06-3007663803core:FurnitureFittings2023-06-3007663803core:MotorVehicles2023-06-3007663803core:CurrentFinancialInstrumentscore:WithinOneYear2024-06-3007663803core:CurrentFinancialInstrumentscore:WithinOneYear2023-06-3007663803core:CurrentFinancialInstruments2024-06-3007663803core:CurrentFinancialInstruments2023-06-3007663803core:ShareCapital2024-06-3007663803core:ShareCapital2023-06-3007663803core:RetainedEarningsAccumulatedLosses2024-06-3007663803core:RetainedEarningsAccumulatedLosses2023-06-3007663803core:FurnitureFittings2023-07-012024-06-3007663803core:MotorVehicles2023-07-012024-06-30076638032022-07-012023-06-3007663803core:FurnitureFittings2023-06-3007663803core:MotorVehicles2023-06-30076638032023-06-3007663803bus:PrivateLimitedCompanyLtd2023-07-012024-06-3007663803bus:SmallCompaniesRegimeForAccounts2023-07-012024-06-3007663803bus:FRS1022023-07-012024-06-3007663803bus:AuditExemptWithAccountantsReport2023-07-012024-06-3007663803bus:FullAccounts2023-07-012024-06-30xbrli:purexbrli:sharesiso4217:GBP